Cytotect CP BiotestCytomegalovirus (CMV) infections - prevention in patients subjected to immunosuppressive therapy, particularly in transplant recipients
Cytotect CP Biotest
New molecular entity
Development and Regulatory status
Jan 20Available in the UK. Packsize 1x10ml(1000 U anti-CMV antibody) and 1x50ml (5000 U anti-CMV antibody) pricing being discussed with the Department of Health .
Jan 20Cytomegalovirus immunoglobulin has been available in selected European countries (Austria, Belgium, Germany, Greece, Hungary, Italy, Netherlands, Portugal) under the brand names Cytotect CP and Megalotect CP [2,3].
Jan 20Approved by the MHRA for prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients .
An immunoglobulin preparation from plasma of donors with a high antibody titer against the CMV. It has a defined and high titer of high avidity anti-CMV antibodies. It also contains IgG antibodies against other pathogens.
In 2015/16, 1,364 people became organ donors when they died and their donations resulted in 3,519 transplants taking place . CMV infection is a frequent complication after transplantation, occurring mainly 30 to 90 days after transplantation. The major risk factors are when the recipient is CMV seronegative and the donor is seropositive, as well as when lymphocyte-depleting antibodies are used .
Cytomegalovirus (CMV) infections - prevention in patients subjected to immunosuppressive therapy, particularly in transplant recipients
Trial or other data
Jan 20The clinical efficacy of CMVIG has been investigated in different settings, including patients who received solid organ and stem cell transplants. In renal transplantation, CMVIG reduced the incidence of CMV infection from 41.7% (control group) to 21.1% (Cytotect group). Other examples include lung transplantation, where the incidence of CMV disease was reduced from 43.3% (control group) to 13.2% (Cytotect group), and bone marrow transplantation, where the incidence of interstitial pneumonitis was reduced from 26.1% to 3.8% .